Kimberly-Clark to Acquire Tylenol Maker Kenvue for Over $40B

Kimberly-Clark intends to amass Kenvue for greater than $40 billion, the 2 firms introduced at the moment.

The information comes amid ongoing controversy round Kenvue’s Tylenol model, which has fielded unsubstantiated claims from the White House linking it to autism in youngsters when taken throughout being pregnant.

Kenvue at the moment introduced that Jon Halvorson will probably be its new chief digital and advertising officer, efficient Nov. 17. The Wall Street Journal first reported the information.

The mixed firm would generate $32 billion yearly however is topic to shareholder and regulatory approvals. The firms anticipate the deal to shut within the second half of 2026.

Founded greater than 150 years in the past in Wisconsin, Kimberly-Clark has roughly 38,000 workers and makes principally paper merchandise, together with Huggies, Kleenex, Depend, Poise, Cottonelle, Scott, and Pull-Ups.

Kenvue was previously the patron well being division of Johnson & Johnson, which introduced its intention to spin off a bunch of manufacturers in late 2021 to focus extra on prescription drugs and medical gadgets. Customer-facing manufacturers like Tylenol, Band-Aid, Zyrtec, Listerine, Neutrogena, and Aveeno landed with Kenvue, which had its IPO in May 2023.

Kimberly-Clark’s plan to amass firm alerts that it doesn’t anticipate the present controversy round Tylenol to have a long-term influence on its worth, although Kimberly-Clark shares did fall after the announcement. Kenvue’s share costs jumped on the information on Nov. 3.